Brain Symptoms of Tuberous Sclerosis Complex: Pathogenesis and Treatment

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• The mammalian target of the rapamycin (mTOR) system is crucial for brain development and function.
• Tuberous sclerosis complex (TSC) is a genetic disorder characterized by mutations in TSC1/TSC2, leading to mTOR hyperactivity.
• Brain-related symptoms in TSC, including epilepsy, intellectual disability, and autism, stem from excessive mTOR signaling.

Purpose of the Study:

• To investigate the role of mTOR hyperactivity in the pathogenesis of TSC-related neurological disorders.
• To explore the therapeutic potential of mTOR inhibitors for treating TSC-associated brain conditions.

Main Methods:

• Review of existing literature on mTOR signaling in the brain and TSC.
• Analysis of the molecular mechanisms linking mTOR hyperactivity to epilepsy and developmental disorders in TSC.
• Evaluation of preclinical and clinical data on mTOR inhibitor efficacy in TSC models and patients.

Main Results:

• mTOR hyperactivity creates a detrimental cycle in TSC, exacerbating epileptic encephalopathy, synaptic dysfunction, and behavioral issues.
• Molecular targeted therapy using mTOR inhibitors has demonstrated efficacy in treating epilepsy in human TSC patients.
• mTOR inhibitors have shown positive effects on autism-like behaviors in TSC model mice.

Conclusions:

• Excessive mTOR activity is a central mechanism driving neurological and behavioral symptoms in TSC.
• mTOR inhibitors represent a promising therapeutic strategy for addressing developmental synaptic disorders associated with TSC.
• Targeting the mTOR pathway offers a potential pharmacological approach for managing intractable epilepsy and autism in TSC.